Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Sodium chloride, Potassium chloride, Tryptophan, Calcium chloride dihydrate, Mannitol, Magnesium chloride hexahydrate, Histidine, Histidine hydrochloride monohydrate, Ketoglutarate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Custodiol is a watery solution with a mixture of electrolytes and amino acids. Custodiol is used: only during cardiac surgery and organ removal as part of organ transplantation in induced and reversible cardiac arrest in open heart surgery (cardioplegia in cardiac surgery operations) for the protection of organs during operations in a bloodless field (heart, kidney, liver) for the preservation of organ transplants: perfusion and cold storage (heart, kidney, liver, pancreas)
2.
e Custodiol
Custodiol must only be used intraoperatively.
Custodiol is given via the Arteria renalis.
Do not use Custodiol: if you are allergic to the active substances or any of the other ingredients of this medicine (listed in section 6).
If the kidney perfused with Custodiol is to be transplanted, in order to maintain protection it must be stored and transported in cold Custodiol at 2°C – 4°C. Protection can then be reliably achieved for 48 hours.
Warnings and precautions D.
Liver transplantation
The following general administration guidelines can be recommended for the liver: Temperature of the solution: 5 °C – 8 °C Perfusion time: Using this dosing and pressure regimen, the perfusion time is 8 minutes (10-15 minutes).
Children and adolescents There is only a limited amount of data regarding the use in children and adolescents.
DR. FRANZ KÖHLER CHEMIE GMBH
Werner-von-Siemens-Str. 14-28, D-64625 Bensheim
www.koehler-chemie.de
V01/12.21
105XXXXX
Other medicines and Custodiol Tell your doctor if you are taking or using, have recently taken or used or might take or use any other medicines. No interactions are known with the following medicines that are used especially during and also frequently before and after the operation:
–
certain medicines to treat heart failure (cardiac glycosides) water tablets (diuretics) medicines to treat the symptoms of angina pectoris (e.g. chest pain or chest tightness). medicines used in conditions with insufficient oxygen supply to the heart muscle (such as nitrates, beta-receptor blockers or calcium antagonists) blood-pressure lowering medicines (as e.g. beta-receptor blockers or calcium channel blocker).
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. Driving and using machines Custodiol has no influence on the ability to drive and use machines. Custodiol contains sodium Custodiol contains 15.0 mmol sodium per 1000 ml. To be taken into consideration by patients on a controlled sodium diet. Custodiol contains 10.0 mmol potassium per 1000 ml. To be taken into consideration by patients with reduced kidney function or patients on a controlled potassium diet.
3.
Custodiol
The treatment regimen and dose must be determined by a specialist. Custodiol must only be given by health care professionals, i.e. a doctor or nurse/male nurse. For dose recommendations please refer to the detailed information at the end of this leaflet for healthcare professionals. If more Custodiol was used than prescribed The uptake of larger amounts of Custodiol into the circulation may lead to volume overload and electrolyte disturbances (too low levels of calcium or sodium in the blood or too high levels of magnesium and potassium in the blood). In this case, your doctor will perform regular blood tests. Note for the physician: More information on overdose can be found at the end of this package leaflet. If you have any further questions on the use of this medicine, ask your doctor or nurse. 4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Side effect with unknown frequency (cannot be estimated from the available data): Systemic use of Custodiol may lead to a temporary reduction in blood pressure during the surgery. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Use only clear, colourless to pale yellow solutions in undamaged containers. For single use only. Once opened, use immediately. Discard any remaining solution.
This leaflet was last revised in 12/2021.
Do not use this medicine if the solution is excessively yellow in colour. After opening, any unused product should be diluted with water and discharged to waste.
————————————————————————————————————–The following information is intended for doctors and healthcare professionals only:
6.
Custodiol
Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder DR. FRANZ KÖHLER CHEMIE GMBH Werner-von-Siemens-Str. 14-28 64625 Bensheim Germany Tel.: +49 6251 1083-0 Fax: +49 6251 1083-146 www.koehler-chemie.de [email protected] Manufacturer DR. FRANZ KÖHLER CHEMIE GMBH Werner-von-Siemens-Str. 14-28, 64625 Bensheim Germany Tel.: 06251 1083-0 – Fax: 06251 1083-146 www.koehler-chemie.de – [email protected]
Keep this medicine out of the sight and reach of children.
Austria Belgium Spain France Italy The Netherlands
Organosol Kardioplege Lösung / Organkonservierungslösung Perisoc Solution de cardioplégie / preservation d'organe Perisoc Solución para cardioplegia y para conservación de órganos Perisoc Solution de cardioplégie / preservation d'organe Custodiol soluzione per cardioplegia / conservazione di organi Cetomedic oplossing voor cardioplegie/bewaaroplossing voor organen
Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of that month.
Portugal United Kingdom
Custodiol Solução para cardioplegia ou para conservação de órgãos Custodiol Solution for Cardioplegia / Organ Preservation
Store in a refrigerator (2 °C – 8 °C). Keep the bottle or plastic bag in the outer carton in order to protect from light.
Posology and method of administration A.
Cardioplegia
Perfusion volume:
This medicinal product is authorised in the Member States of the EEA under the following names: 5.
Overdose The uptake of larger volumes of Custodiol into the systemic circulation can lead to volume overload and electrolyte disturbances (hypocalcaemia, hyponatraemia, hypermagnesaemia, hyperkalaemia). Regular monitoring of serum electrolytes is recommended following systemic application. Complete inactivation makes the myocardium susceptible to distension. It is therefore important to ensure adequate ventricular drainage. The recommended perfusion volumes and pressures should not be exceeded. Special caution is required for the hearts of children and infants.
Perfusion pressure (= pressure in the aortic root): In adults, initially 110 to 140 cm hydrostatic pressure, equivalent to 80 to 110 mm Hg are used. The surgeon has to make sure, that the aortic valve is closing properly. After onset of cardiac arrest, the pressure is reduced by half to 50 to 70 cm hydrostatic pressure, equivalent to 40 to 60 mmHg. In case of severe coronary stenosis, a higher pressure should be used (approx. 50 mmHg). Perfusion time: Using this dosing and pressure regimen, the perfusion time must be 6-8 minutes in order to achieve myocardial homogeneous equilibration and this time should not be shorter under any circumstance. Perfusion technique: After clamping the aorta and simultaneous "venting" of the left ventricle, the solution will be administered antegrade. Cardioplegic perfusion can be performed by either a roller pump with constant volume or by gravity (after cardiac arrest, the solution bag must be kept at 40-50 cm above the level of the heart). Administration guidelines for additional cardioplegic perfusion: If cardioplegic reperfusions gets necessary, perfusion time should be 1-2 minutes (equivalent to 200 – 400 ml); the perfusion pressure should correspond to the pressure in the last minute of the initial cardioplegic coronary perfusion. In most cases, the patient is placed in moderate systemic hypothermia. Usually, Custodiol is given via the aortic root. In case of aortic insufficiency and of dissection of thoracic aortic surgery, the solution must be administered by selective coronary perfusion into the coronary ostia. Due to a limited amount of clinical data a positive benefit/risk ratio for the use of Custodiol in short surgery procedures (<90 minutes) has not been confirmed yet. Administration guidelines for retrograde perfusion on coronary sinus Do not exceed 30 mmHg infusion pressure (usually about 250 ml/min) for a retrograde infusion of the same duration as an antegrade infusion (6-8 minutes minimum).
What Custodiol contains The active substances are sodium chloride, potassium chloride, magnesium chloride hexahydrate, histidine, histidine hydrochloride monohydrate, tryptophan, mannitol, calcium chloride dihydrate, α-ketoglutaric acid. The other excipients are water for injections and potassium hydroxide (for pH adjustment).
What Custodiol looks like and contents of the pack Custodiol is a clear solution and is available in the following pack sizes: 500 ml bottles 1000 ml bottles 1000 ml bags 2000 ml bags 5000 ml bags 10 x 500 ml bottles 6 x 1000 ml bottles 6 x 1000 ml bags 4 x 2000 ml bags 2 x 5000 ml bags
Custodiol Solution for cardioplegia /organ preservation comes as solution. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Custodiol Solution for cardioplegia /organ preservation is sodium chloride, potassium chloride, tryptophan, calcium chloride dihydrate, mannitol, magnesium chloride hexahydrate, histidine, histidine hydrochloride monohydrate, ketoglutarate.
This leaflet reproduces the patient information leaflet approved for Custodiol Solution for cardioplegia /organ preservation, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
• Cardioplegia in cardiac surgery operations,
• protection of organs during operations in a bloodless field (heart, kidney, liver),
• preservation of organ transplants: perfusion and cold storage (heart, kidney, liver, pancreas).
A. Cardioplegia
Perfusion volume:
The perfusion rate is 1 ml/minute/gram heart weight. The normal weight of the heart accounts for approximately 0.5% of body weight in an adult, leading to a total volume of Custodiol between 1.5 and 2 litres.
Temperature of the solution 6° C – 10° C in open heart procedure
Perfusion pressure (= pressure in the aortic root):
In adults, initially 110 to 140 cm hydrostatic pressure, equivalent to 80 to 110 mmHg are used. The surgeon has to make sure, that the aortic valve is closing properly. After onset of cardiac arrest, the pressure is reduced by half to 50 – 70 cm hydrostatic pressure, equivalent to 40 – 60 mmHg. In case of severe coronary stenosis, a higher pressure should be used (approx. 50 mmHg).
Perfusion time:
Using this dosing and pressure regimen, the perfusion time must be 6 – 8 minutes in order to achieve myocardial homogeneous equilibration and this time should not be shorter under any circumstances.
Perfusion technique:
After clamping the aorta and simultaneous “ venting” of the left ventricle, the solution will be administered antegrade. Cardioplegic perfusion can be performed by either a roller pump with constant volume or by gravity (after cardiac arrest, the solution bag must be kept at 40-50 cm above the level of the heart).
Administration guidelines for additional cardioplegic perfusion:
If cardioplegic reperfusions gets necessary, perfusion time should be 1 – 2 minutes (equivalent to 200 – 400 ml); the perfusion pressure should correspond to the pressure in the last minute of the initial cardioplegic coronary perfusion.
In most cases, the patient is placed in moderate systemic hypothermia.
Usually, Custodiol is given via the aortic root. In case of aortic insufficiency and of dissection of thoracic aortic surgery, the solution must be administered by selective coronary perfusion into the coronary ostia.
Due to a limited amount of clinical data a positive benefit/risk ratio for the use of Custodiol in short surgery procedures (<90 minutes) has not been confirmed yet.
Administration guidelines for retrograde perfusion on coronary sinus:
Do not exceed 30 mmHg infusion pressure (usually about 250 ml/min) for a retrograde infusion of the same duration as an antegrade infusion (6-8 minutes minimum).
B. Heart transplantation
Following cross-clamping of the ascending aorta, the heart is perfused for at least 6 minutes. This follows a perfusion rate of 1 ml/minute per gram of heart weight, up to a total amount of 3.5 litres or more for adults.
Perfusion pressure (= pressure in the aortic root):
In adults, initially 110 to 140 cm hydrostatic pressure, equivalent to 80 to 110 mmHg are used. The surgeon has to make sure, that the aortic valve is closing properly. After onset of cardiac arrest, the pressure is reduced by half to 50 – 70 cm hydrostatic pressure, equivalent to 40 – 50 mmHg. In case of severe coronary stenosis, a higher pressure should be used (approx. 50 mmHg).
Perfusion time:
Using this dosing and pressure regimen, the perfusion time must be 6 – 8 minutes in order to achieve myocardial homogeneous equilibration and this time should not be shorter under any circumstances.
Perfusion technique:
After clamping the aorta and simultaneous “ venting” of the left ventricle, the solution will be administered antegrade. Cardioplegic perfusion can be performed by either a roller pump with constant volume or by gravity (after cardiac arrest, the solution bag must be kept at 40-50 cm water column above the level of heart).
If the heart perfused with Custodiol is to be transplanted, in order to maintain protection, it must be stored and transported in cold Custodiol at 2° C – 4° C. Protection can then be reliably achieved for up to five hours.
C. Kidney transplantation
The following general administration guidelines are recommended for the kidney:
Temperature of the solution: 5° C – 8° C
Perfusion volume:
Perfusion with 1.5 ml Custodiol per minute and gram of estimated kidney weight (the normal weight of the kidney in an adult is approximately 150 grams). Including 500 ml storage solution, this leads to a total volume of ca. 2.5 litres of Custodiol per organ.
Perfusion pressure (renal artery):
120 to 140 cm water column above the level of the kidney equivalent to approximately 90 to 110 mmHg at the tip of the perfusion catheter in the renal artery.
Perfusion time:
Using this dosing and pressure regimen, the perfusion time is 8 – 10 minutes. This time is necessary in order to achieve homogeneous equilibration of the extracellular space of the kidney (including the interstitium and tubular system), and this time must not be shorter under any circumstances.
Accompanying measures:
In order to derive maximum benefit from the protective efficiency of Custodiol in the kidney, it is important to ensure pronounced diuresis prior to the start of perfusion (pharmacologically and/or hydration of the patient).
Custodiol is given via the Arteria renalis.
If the kidney perfused with Custodiol is to be transplanted, in order to maintain protection it must be stored and transported in cold Custodiol at 2° C – 4° C. Protection can then be reliably achieved for 48 hours.
D. Liver transplantation
The following general administration guidelines can be recommended for the liver:
Temperature of the solution: 5° C – 8° C
Perfusion time:
Using this dosing and pressure regimen, the perfusion time is 8 minutes (10-15 minutes).
Perfusion volume:
If the liver, pancreas and kidneys are to be protected all together in a so-called donor organism, a perfusion quantity of 150 – 200 ml {Invented name}/kg body weight is necessary. With this "overall protection", this is equivalent to a perfusion quantity of cold Custodiol-solution of 8 – 12 l in patients weighing approximately 70 – 80 kg.
If only the liver or a part of the liver (e.g. in the case of live donation) is being removed without other organs, the perfused volume is reduced accordingly.
Perfusion pressure:
100 cm water column above the level of the liver.
Accompanying measures:
In an organ donor, the blood must be heparinised prior to the start of perfusion. The bile ducts should be abundantly rinsed with a minimum of 100 ml cold Custodiol inside or outside the body - usually with the aid of a small-calibre catheter.
The surgically removed liver is then packed or sent for transplantation immersed in cold Custodiol. The organ must be fully covered by cold Custodiol. A cold ischaemia time <10 hours is advised.
E. Pancreas
Perfusion volume and time should be adjusted from the liver to the much smaller graft, which is the pancreas. Optimal perfusion depends on a thorough cooling and exsanguination of the organ. This can be achieved with approximately 3-4 liters of Custodiol. Overtreatment and reflushing of the graft should be avoided.
Previous research suggests that care must be taken not to overflush the pancreas allograft with any preservation solution as this may lead to allograft oedema and pancreatitis and there seems to be a clear benefit to maintaining as brief a cold ischaemia time as possible. A cold ischaemia time <10 hours is advised.
With higher flush volumes (>5 l) and longer ischaemic times (>12 h), there may be a risk of allograft pancreatitis.
Paediatric population
There is only a limited amount of data regarding the use in children and adolescents.
Heart
Perfusion pressure:
In neonates and infants, initially 110 to 120 cm water column above the level of the heart, equivalent to 80 to 90 mmHg; after the onset of cardiac arrest, reduction to 40 to 50 cm water column, equivalent to 30 to 40 mmHg. In patients with severe coronary sclerosis, higher pressures over a longer period of time should be maintained. The right atrium should be opened and the cardioplegia completely aspirated outside the bypass circuit to avoid haemodilution.
The perfusion volume depends on the age of the children: 50 ml/kg (first month of life), 30 ml/kg (2nd month-1st year), 20 ml/kg (>1st year), while perfusion time is 4-6 minutes in all cases. For example, an estimated heart weight of 50 g would require approximately 350 ml.
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Only colourless to pale yellow solutions from intact containers should be used.
Custodiol will be taken out of the refrigerator just before use.
Not for systemic administration. Custodiol is not suitable for replenishment of circulatory volume or for replacement of amino acids or electrolytes.
As a precaution, in the event of an emergency operation on the heart during pregnancy the cardioplegic solution should be removed by suction from the right atrium and ventricle of the heart after the end of the operation.
Depending on the underlying operation, the method used, the duration of the procedure and size of the patient, up to 3 l of the cardioplegic solution can enter the systemic circulation. This can result in a fall in the serum levels of calcium and sodium. Appropriate laboratory monitoring should therefore be undertaken.
Inactivation of the heart accounts for its susceptibility to distension. Thus, relaxation of the left ventricle must take place when inducing cardioplegia and is important to ensure adequate ventricular drainage. The recommended perfusion volumes and pressures should not be exceeded. Special caution is required for the hearts of children and infants. For details regarding perfusion volumes, perfusion times and perfusion technique please refer to the recommendations given in section 4.2.
Because the sodium concentration in Custodiol is lower than in blood, administration of Custodiol may cause hyponatraemia. It is important to note that this hyponatremia does not modify blood osmolarity because Custodiol has an osmolarity close to that of blood. Therefore, no deleterious consequences are expected in the patient from the decreased sodium level caused by Custodiol administration.
In order to mitigate the haemodilution consequences associated with the use of Custodiol in cardiac surgery, it is recommended to use hemofiltration during CEC.
In case of improper permanent perfusion with insufficiently cooled cardioplegic solution (>20° C and >15 minutes), a so-called calcium paradox can be initiated, which occurs after reconnection to the circulation as destruction of the cardiac muscle cells. This risk does not apply to solutions with a sodium content of <20 mmol/l, if the calcium content is >10 μ mol/l and the solution is cold, i.e. <15° C and perfused continuously for a limited period of time i.e. no longer than 20 minutes.
Immersion of a whole heart in cold Custodiol, however, does not represent a risk in the sense of a calcium paradox even when used over hours - e. g. for the time interval between removal of the organ from the donor and transplantation into a recipient. Therefore, with proper application, a calcium paradox is virtually impossible even under extreme experimental conditions.
Reversal of cardioplegia occurs by re-opening the aorta. It is advisable to initially perfuse the myocardium, which is very flaccid as a result of the cardioplegia, with a low blood pressure (mean arterial pressure of 40 mmHg for approximately 2 minutes). As the activity of the myocardium increases, the perfusion pressure can be returned to normal. Cardiac activity frequently returns with a spontaneous rhythm, otherwise one defibrillation is generally sufficient.
Custodiol contains 15.0 mmol sodium per 1000 ml. To be taken into consideration by patients on a controlled sodium diet.
Custodiol contains 10.0 mmol potassium per 1000 ml. To be taken into consideration by patients with reduced kidney function or patients on a controlled potassium diet.
This solution is not intended for use with a continuous perfusion machine.
Interactions with medicinal products such as glycosides, diuretics, nitrates, antihypertensive agents, beta-receptor blockers and calcium antagonists which are used in the perioperative period particularly frequently are not known.
Pregnancy and breast-feeding
Custodiol must only be used after careful benefit/risk assessment in pregnancy and breast-feeding (see also section 4.4).
For safety reasons, in case of emergency operation during pregnancy, the cardioplegic solution should be removed by aspiration from the right atrium and ventricle of the heart after the end of the operation.
Fertility
It is not known whether the active substance of Custodiol or their metabolites have an effect on fertility.
Custodiol has no or negligible influence on the ability to drive and use machines.
Cardiac/vascular disorders
Not known (frequency cannot be estimated from the available data):
Therapeutic use of Custodiol for perfusion may result in a blood pressure reduction, as storage of the solution may result in the formation of a reaction product (micimopine) from the components L-histidine and α -ketoglutaric acid, which may reduce blood pressure by blocking the angiotensin II receptors of subtype 1.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard. or search for MHRA Yellow Card in the Google Play or Apple App Store
The uptake of larger volumes of Custodiol into the systemic circulation can lead to volume overload and electrolyte disturbances (hypocalcaemia, hyponatraemia, hypermagnesaemia, hyperkalaemia). Regular monitoring of serum electrolytes is recommended following systemic application.
Complete inactivation makes the myocardium susceptible to distension. The recommended perfusion volumes and pressures should not be exceeded.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
⚠ Not the same combination. This medicine contains Sodium chloride, Potassium chloride, Tryptophan, Calcium chloride dihydrate, Mannitol, Magnesium chloride hexahydrate, Histidine, Histidine hydrochloride monohydrate, Ketoglutarate. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Not the same combination. This medicine contains Sodium chloride, Potassium chloride, Tryptophan, Calcium chloride dihydrate, Mannitol, Magnesium chloride hexahydrate, Histidine, Histidine hydrochloride monohydrate, Ketoglutarate. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Custodiol Solution for cardioplegia /organ preservation. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.